Last Price
15.98
Today's Change
+0.06 (0.37%)
Day's Change
15.14 - 16.00
Trading Volume
361,958
Market Cap
926 Million
Shares Outstanding
57 Million
Avg Volume
537,929
Avg Price (50 Days)
17.04
Avg Price (200 Days)
18.43
PE Ratio
-5.22
EPS
-3.06
Earnings Announcement
06-Nov-2024
Previous Close
15.92
Open
15.84
Day's Range
15.1454 - 16.005
Year Range
7.64 - 30.189
Trading Volume
361,958
1 Day Change
0.38%
5 Day Change
1.72%
1 Month Change
-2.20%
3 Month Change
-7.20%
6 Month Change
-43.73%
Ytd Change
50.90%
1 Year Change
63.06%
3 Year Change
-32.14%
5 Year Change
-46.57%
10 Year Change
-46.57%
Max Change
-46.57%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.